AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval
Long Wait For First Tremelimumab Approval Could Soon Be Over
Executive Summary
AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.
You may also be interested in...
Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.